Fig. 3

Clustering of peripheral blood and tissue infiltrating senescent CD57^pos/CD28^neg/CD16^pos T_EMRA Vδ2^pos T cells in patients affected by liver metastasis of colorectal cancer and underwent chemotherapy. a t-SNE analysis plots in CLM patients underwent CHT (n = 16) showing the cluster of PB CD57^pos/ Vδ2^pos T cells (red, upper left plot) co-expressing CD16 (blue, upper right plot), CD45RA but not CD27 (T_EMRA in green, lower left plot) and negative for CD28 (black, lower right plot). b t-SNE analysis plots (left) and statistical dot plot graph (right) showing the frequency (%) of senescent PB CD57^pos/CD28^neg/CD16^pos T_EMRA Vδ2^pos T cells in healthy donors (upper plot; n = 12; mean age: 51.7 ± 10.8) and CLM underwent CHT (lower plot; n = 16; mean age: 61 ± 10.7). c Summary dot plot analysis showing the frequencies (%) of liver tumor-associated Vδ2^pos T cells within total CD3^pos T lymphocytes or CD57^pos/Vδ2^pos T cells in CLM patients receiving CHT regimen (black circles; n = 58) and naïve for CHT (white circles; n = 13). d Statistical dot plot analysis showing the frequencies (%) of CD57^pos cells on liver tumor infiltrating Vδ2^pos T cells in CLM patients underwent CHT regimen and sub-divided in two groups of respectively < (white circles; n = 22) and ≥ (black circles; (n = 27) of 60 years old. e t-SNE analysis plots (left plots) and statistical chart (right graph) of the CHT-mediated changes in the frequency (%) of the age-related, liver tumor infiltrating CD57^posCD28^negCD16^posT_EMRA Vδ2^pos T cell cluster in CHT treated CLM patients (lower plot, n = 25; mean age: 61 ± 10.7) and naïve for CHT patients (upper plot, n = 13; mean age: 69.5 ± 8.1)